Exogene
Exogene use deep learning to unlock the discovery of innovative TCR-based therapies for cancer treatment.
Human T-cells use T-cell receptors to eliminate diseased cells. This natural phenomenon can be harnessed for the development of TCR-based therapies to eradicate solid tumors. However, safe, high-affinity TCRs against cancer targets are rare and hard to identify using traditional wet-lab methods.
Exogene’s generative AI platform enables comprehensive mining of the TCR sequence space to discover completely novel, high-affinity and non-cross-reactive TCRs against targets shared across patients and tumor types.
Founders
Federico Paoletti
CEO
Federico is a computational biologist with deep expertise in mathematical modeling and molecular biophysics. He holds a PhD in Molecular and Computational Oncology from the University of Oxford and has previously worked at the World Health Organization assessing cancer prevention strategies.
Andrea Mambrini
CTO
Andrea is an experienced machine learning scientist. He holds a PhD in Bio-Inspired Computation and has several years of experience building AI. He previously led the ML team at Portent.io (acquired by Yougov) and has worked at the European Space Agency, Honda Research Institute and Vodafone.
Milestones
Founded at Entrepreneur First
Seed ($2 million) led by Selvedge Ventures